Status:

COMPLETED

Melanoma Molecular Profiling Analysis

Lead Sponsor:

University of Pittsburgh

Collaborating Sponsors:

Schering-Plough

Conditions:

Melanoma

Eligibility:

All Genders

12+ years

Brief Summary

There is a significant need to develop new and more effective ways to treat melanoma that will decrease patient morbidity and mortality. This protocol intends to collect and process a portion (\< 20% ...

Eligibility Criteria

Inclusion

  • Primary melanoma with the following Breslow thickness and stage
  • ≥ 2 mm with ulceration, T3b
  • ≥ 4 mm without (T4a) or with (T4b) ulceration
  • Patients with a biopsied tumor that has not been widely resected will also be eligible for study according to the above-specified criteria for tumor thickness and stage.
  • Age 12 years or older.
  • Patients must have documented hemoglobin level of 10g/dL or higher. This can be drawn on the day of consent, or be documented from a previous visit within the past 30 days
  • Subjects must have provided written, informed consent prior to any study procedures: collection of blood and LN tissue specimens for this protocol.

Exclusion

  • Serious illnesses that may be considered a contraindication to surgery as determined by the physician investigator. If a subject is cleared for surgery as clinically indicated (wide excision of the primary melanoma and sentinel lymph node biopsy), subject would be eligible.
  • Any significant psychiatric disease, medical intervention, or other condition, which in the opinion of the Principal Investigator or Co-Investigators, could prevent adequate informed consent or compromise participation in the clinical trial.
  • Active infection or antibiotics within one-week prior to study
  • Systemic steroid or other immunosuppressive therapy administered for more than 10 days within 4 weeks of enrollment.

Key Trial Info

Start Date :

May 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 22 2019

Estimated Enrollment :

237 Patients enrolled

Trial Details

Trial ID

NCT00889980

Start Date

May 1 2008

End Date

July 22 2019

Last Update

June 9 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232